By Josh BeckermanEnsysce Biosciences shares rose 31% to $2.36 Monday after HC Wainwright initiated coverage with a $9 price target and buy rating. Volume was 11.3 million shares, compared with a 65-day average of 640,450. The stock has a 52-week range of $1.75 to $180.

Source: Wall Street Journal July 03, 2023 19:44 UTC